Action 0VY I-MAB
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués I-Mab Börse Stuttgart

Actions

0VY

US44975P1030

Temps Différé Börse Stuttgart
Autres places de cotation
 08:04:48 05/07/2024 		Varia. 5j. Varia. 1 janv.
1,42 EUR 0,00% Graphique intraday de I-Mab -11,25% -12,88%
06/06 I-Mab nomme Phillip Dennis au poste de directeur médical CI
05/06 I-Mab collabore avec Bristol-Myers pour évaluer le givastomig dans une étude de combinaison pour les cancers de l'estomac et de l'œsophage MT

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
AQ
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers
PR
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024
AQ
I-Mab to Participate at the Jefferies Global Healthcare Conference
PR
I-MAB Filed 2023 Annual Report on Form 20-F
PR
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
AQ
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
PR
I-Mab Announces Closing of the Divestiture of Business Operations in China
PR
I Mab : Resignations of Director and Senior Management - Form 6-K
PU
I-Mab Signs Agreement to Divest its Assets and Business Operations in China
AQ
I-Mab Announces Participation at Jefferies and Piper Conferences in November
PR
I-Mab - Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration for Primary Membranous Nephropathy
AQ
I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023
PR
I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023
PR
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503
AQ
I Mab : Regains Global Rights to Lemzoparlimab - Form 6-K
PU
I-Mab Announces Upcoming Participation at September Conferences
PR
I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates
AQ
I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023
PR
TRACON Pharmaceuticals Announces Collection of Arbitration Award from I-Mab Biopharma
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action IMAB
  4. Action 0VY
  5. Actualités I-Mab
  6. Communiqués